I125 irradiation stent for treatment of hepatocellular carcinoma with portal vein thrombosis: A meta-analysis
- PMID: 33455874
- DOI: 10.1016/j.canrad.2020.12.003
I125 irradiation stent for treatment of hepatocellular carcinoma with portal vein thrombosis: A meta-analysis
Abstract
Purpose: A meta-analysis aimed to systematically evaluate the safety and efficiency of I125 irradiation stent placement for patients with hepatocellular carcinoma (HCC) combined with portal vein tumor thrombosis (PVTT).
Materials and methods: The Cochrane library, PubMed/Medline, EMBASE, CNKI, Wanfang Data and CQVIP were systematically screened out from the earliest to December 2019. The qualities of all included studies were assessed. The primary endpoints were the 6-month, 12-month stent cumulative patency rate and 6-month, 12-month, 24-month overall survival rate while the secondary endpoints were the objective response rate of PVTT, main portal venous pressure changes and treatment-related adverse events. Our meta-analysis was conducted using Stata 12.0 software.
Results: Totally seven studies with 1018 patients were included in the final analysis, in which 602 patients received TACE and I125 irradiation stent placement, and 416 patients in control group underwent TACE and stent placement without endovascular brachytherapy (EVBT). Meta-analysis showed that the I125 irradiation stent improved the cumulative stent patency rates in 6months [OR=1.65, 95% CI (1.32-2.05), P<0.001] and 12months [OR=2.55, 95% CI (1.90-3.42), P<0.001] and the survival rates in 6months [OR=1.77, 95% CI (1.41-2.22), P<0.001], 12months [OR=3.14, 95% CI (2.24-4.40), P<0.001] and 24months [OR=7.39, 95% CI (3.55-15.41), P<0.001]. However, there was no difference in the objective response rate of PVTT [OR=1.13, 95% CI (0.87-1.48), P=0.365], main portal venous pressure and the occurrence adverse event [OR=0.88, CI=0.72-1.08, P=0.212] between two groups.
Conclusion: I125 irradiation stent seems to be more effective in treating hepatocellular carcinoma with portal vein tumor thrombosis. The usage of portal vein stent combined endovascular brachytherapy has the potential to act as an alternative therapy for HCC with PVTT. On account of the limitation of studies included, more studies with high-level evidence, such as RCTs, are requisite to support the above promising results.
Keywords: Carcinome hépatocellulaire; Chimioembolisation transartérielle; Curiethérapie endovasculaire; Endovascular brathytherapy; Hepatocellular carcinoma; I(125) irradiation stent; Meta-analysis; Méta-analyse; Portal vein tumor thrombus; Stent d’iode125; Thrombose tumorale de la veine porte; Transarterial chemoembolization.
Copyright © 2020. Published by Elsevier Masson SAS.
Similar articles
-
Endovascular brachytherapy combined with stent placement and TACE for treatment of HCC with main portal vein tumor thrombus.Hepatol Int. 2016 Jan;10(1):185-95. doi: 10.1007/s12072-015-9663-8. Epub 2015 Sep 4. Hepatol Int. 2016. PMID: 26341514
-
125I seed implantation for hepatocellular carcinoma with portal vein tumor thrombus: A systematic review and meta-analysis.Brachytherapy. 2019 Jul-Aug;18(4):521-529. doi: 10.1016/j.brachy.2019.01.014. Epub 2019 Apr 3. Brachytherapy. 2019. PMID: 30954398
-
Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus.World J Gastroenterol. 2017 Nov 21;23(43):7735-7745. doi: 10.3748/wjg.v23.i43.7735. World J Gastroenterol. 2017. PMID: 29209114 Free PMC article. Clinical Trial.
-
Safety and Efficacy of Irradiation Stent Placement for Malignant Portal Vein Thrombus Combined with Transarterial Chemoembolization for Hepatocellular Carcinoma: A Single-Center Experience.J Vasc Interv Radiol. 2017 Jun;28(6):786-794.e3. doi: 10.1016/j.jvir.2017.02.014. Epub 2017 Apr 7. J Vasc Interv Radiol. 2017. PMID: 28396192
-
125I Irradiation Stent for Hepatocellular Carcinoma with Main Portal Vein Tumor Thrombosis: A Systematic Review.Cardiovasc Intervent Radiol. 2020 Feb;43(2):196-203. doi: 10.1007/s00270-019-02346-y. Epub 2019 Oct 10. Cardiovasc Intervent Radiol. 2020. PMID: 31602496
Cited by
-
Transjugular intrahepatic portosystemic shunt with radioactive seed strand for main portal vein tumor thrombosis with cirrhotic portal hypertension.World J Gastrointest Surg. 2022 Jun 27;14(6):567-579. doi: 10.4240/wjgs.v14.i6.567. World J Gastrointest Surg. 2022. PMID: 35979417 Free PMC article.
-
Short-term efficacy assessment of transarterial chemoembolization combined with radioactive iodine therapy in primary hepatocellular carcinoma.World J Gastrointest Surg. 2023 Jan 27;15(1):105-113. doi: 10.4240/wjgs.v15.i1.105. World J Gastrointest Surg. 2023. PMID: 36741065 Free PMC article. Clinical Trial.
-
Clinical application of spectral CT perfusion scanning in evaluating the blood supply source of portal vein tumor thrombus in hepatocellular carcinoma.Front Oncol. 2024 Jan 17;13:1348679. doi: 10.3389/fonc.2023.1348679. eCollection 2023. Front Oncol. 2024. PMID: 38304029 Free PMC article.
-
Downstaging and Conversation Strategy for Advanced Hepatocellular Carcinoma with Portal Vein Branch Tumor Thrombus: TACE, 125I Seed Implantation, and RFA for Hepatocellular Carcinoma with Portal Vein Branch Tumor Thrombus.J Hepatocell Carcinoma. 2023 Feb 14;10:231-240. doi: 10.2147/JHC.S392293. eCollection 2023. J Hepatocell Carcinoma. 2023. PMID: 36819987 Free PMC article.
-
Characteristics of HCC Patients with Portal Vein Thrombosis: Albumin and Survival.Oncology. 2025;103(8):667-676. doi: 10.1159/000542774. Epub 2024 Dec 9. Oncology. 2025. PMID: 39653023 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous